Disclosures

Neeraj Agarwal, MD

Professor of Medicine; Huntsman Cancer Institute Presidential Endowed Chair of Cancer Research; Co-Leader, Center of Investigational Therapeutics; Director, Genitourinary Oncology Program, Huntsman Cancer Institute, University of Utah, Salt Lake City

Served on scientific advisory board or as a consultant or expert witness for Astellas Pharma US, AstraZeneca, Aveo Pharmaceuticals, Bayer HealthCare, Bristol Myers Squibb, Eisai, EMD Serono, Exelixis, Genentech, Immunomedics, Janssen, MEI Pharma, and Seattle Genetics

Jennifer R. Brown, MD, PhD

Associate Professor of Medicine, Dana-Farber Cancer Institute, Boston

Received clinical research support/data safety monitoring board from Acerta Pharma, BeiGene, Catapult, Eli Lilly and Company, and MEI Pharma

Served on scientific advisory board or as a consultant or expert witness for AbbVie, Acerta Pharma, BeiGene, Catapult, Celgene, Juno Therapeutics, MEI Pharma, MorphoSys AG, Novartis, and Pfizer

Alexander Drilon, MD

Chief of Early Drug Development, Memorial Sloan Kettering Cancer Center, New York

Received honoraria and consulting fees for advisory boards from Ignyta/F. Hoffmann–La Roche/Genentech, Loxo/Bayer/Eli Lilly, TP Therapeutics, AstraZeneca, Pfizer, Blueprint Medicines, Takeda/Ariad/Millennium, Helsinn, BeiGene, BerGenBio, Hengrui Therapeutics, Exelixis, Tyra Biosciences, Verastem, MORE Health, AbbVie, 14ner/Elevation Oncology, Remedica Ltd, ArcherDX, Monopteros, Novartis, EMD Serono, Liberum, Repare RX, and Melendi

Received associated research funding paid to institution by Pfizer, Exelixis, Taiho, Teva, GlaxoSmithKline, and PharmaMar

Received research funding from Foundation Medicine; royalties from Wolters Kluwer; other from Merck, Puma, Merus, and Boehringer Ingelheim; CME honoraria from Medscape, OncLive, PeerVoice, Physicians Education Resources, Targeted Oncology, Research to Practice, Axis, Peerview Institute, Paradigm Medical Communications, WebMD, and MJH Life Sciences

David S. Ettinger, MD, FACP, FCCP

Alex Grass Professor of Oncology, The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore

Served on scientific advisory board or as a consultant or expert witness for BeyondSpring Pharmaceuticals and Takeda Pharmaceuticals North America

Thomas Flaig, MD

Professor, Medicine-Medical Oncology and Associate Dean for Clinical Research, School of Medicine, University of Colorado Cancer Center, Aurora

Served on scientific advisory board or as a consultant or expert witness for Janssen and Seattle Genetics

Was issued patent for work done as an employee of Aurora Oncology, University of Colorado

William J. Gradishar, MD

Director, Clinical Network; Chief, Hematology and Oncology, Robert H. Lurie Comprehensive Cancer Center of Northwestern University, Chicago

Received clinical research support/data safety monitoring board from Daiichi Sankyo, Genentech, Immunomedics, and Seattle Genetics

Served on scientific advisory board or as a consultant or expert witness for AstraZeneca, Merck & Co, and Pfizer

Robert I. Haddad, MD

Chief, Division of Head and Neck Oncology and Institute Physician, Dana-Farber Cancer Institute; Professor of Medicine, Harvard Medical School, Boston

Received clinical research support/data safety monitoring board from AstraZeneca Pharmaceuticals, Bristol Myers Squibb, Genentech, GlaxoSmithKline, Kura Oncology, Merck & Co, and Pfizer

Served on scientific advisory board or as a consultant or expert witness for Achilles, AstraZeneca Pharmaceuticals, Bayer HealthCare, BioNTech, Bristol Myers Squibb, Celgene, Eisai, Genentech, Gilead Sciences, GlaxoSmithKline, IO Biotechn, Kura Oncology, Merck & Co, and Vaccinex

Served on promotional advisory boards, as a consultant, or on speakers bureau for isa nanobiotix

Prashant Kapoor, MD

Assistant Professor of Medicine and Oncology (Division of Hematology), Mayo Clinic, Rochester, Minnesota

Served on scientific advisory board or as a consultant or expert witness for AbbVie, Cellectar, and Sanofi

Received research funding from AbbVie, Amgen, GlaxoSmithKline, Janssen, Karyopharm, Sanofi, and Takeda

Received honoraria from BeiGene, Janssen, Karyopharm, and Takeda

Shaji K. Kumar, MD

Professor of Medicine, Mayo Clinic, Rochester, Minnesota

Received clinical research support/data safety monitoring board from AbbVie, Allogene, Bristol Myers Squibb, Carsgen, Celgene, GlaxoSmithKline, MedImmune, Oncogene, Roche Laboratories, Takeda Pharmaceuticals North America, and Tenebio

Served on scientific advisory board or as a consultant or expert witness for AbbVie, BeiGene, Celgene, Cellectar, GlaxoSmithKline, Oncopeptides, Roche Laboratories, sanofi-aventis U.S., and Takeda Pharmaceuticals North America

Karl D. Lewis, MD

Associate Professor, Division of Medical Oncology, University of Colorado Denver School of Medicine

Received honoraria from Incyte and Array BioPharma

Received research funding from Roche, Merck, Incyte, Array BioPharma, Nektar, Iovance Biotherapeutics, and Bristol Myers Squibb

Served as a consultant or advisor to Array BioPharma, Merck, Roche, and Regeneron Pharmaceuticals

Rebecca Olin, MD, MS

Associate Professor, Department of Medicine (Hematology/Oncology), University of California, San Francisco

Received clinical research support from or served on data safety monitoring board for Astellas Pharma US, AstraZeneca Pharmaceuticals, Daiichi Sankyo, Genentech, MedImmune, Mirati, Novartis, Pfizer, Spectrum Pharmaceuticals, and Takeda Pharmaceuticals North America

Served on scientific advisory board or as a consultant or expert witness for AbbVie, Amgen, and Astellas Pharma U.S.

Gregory J. Riely, MD, PhD

Vice Chair, Clinical Research, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York

Received institutional research support from Merck, Mirati, Novartis, Pfizer, Roche, and Takeda Pharmaceuticals North America

Served as uncompensated consultant to Daiichi Sankyo, Mirati, and Pfizer

Sandy Srinivas, MD

Professor of Medicine, Stanford University Medical Center, Stanford, California

Received clinical research support from or served on a data safety monitoring board for AstraZeneca Pharmaceuticals, Bayer HealthCare, Bristol Myers Squibb, Clovis Oncology, Eisai, Exelixis, Genentech, Merck &  Co, Pfizer, Seattle Genetics, and Tracon Pharmaceuticals

Served on scientific advisory board or as a consultant or expert witness for AstraZeneca, Bayer HealthCare, Bristol Myers Squibb, Eisai, Exelixis, Merck & Co, and Seattle Genetics

Lori J. Wirth, MD

Associate Professor in Medicine, Harvard Medical School; Medical Director, Center for Head and Neck Cancers, Massachusetts General Hospital, Boston

Served on scientific advisory board or as a consultant or expert witness for Bayer Healthcare, Blueprint Medicines, Eisai, Eli Lilly and Company, Exelixis, Genentech, Loxo Oncology, and Merck & Co

Medical Writers:

The following medical writers reported no conflicts of interest.

Jenna Carter, PhD, Vanessa A. Carter, BS; Cordi Craig, MS; Hope Craig; Joseph Cupolo; Celeste L. Dixon; Joseph Fanelli; Julia Fiederlein; Lauren Harrison, MS; Kelly M. Hennessey, PhD; Justine Landin, PhD; Susan London; Joshua Madera, MS; Margie Miller; Anna Nowogrodzki; Susan Reckling; Kayci Reyer; Emily Rhode; Jocelyn Solis-Moreira, MS; Joshua Swore

Sarah Campen, PharmD: Her spouse works for Johnson & Johnson/Janssen.

Noelle L. Cutter, PhD: She serves on the editorial board for The Journal of Biomedical Sciences.